PA21 clinical trials
Also written PA21.
How each study uses PA21 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2011 (7)
| Year | Studies |
|---|---|
| 2011 | 7 |
| 2012 | 1 |
| 2013 | 3 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Vifor Pharma (7) · Kissei Pharmaceutical Co., Ltd. (5) · Vifor Fresenius Medical Care Renal Pharma (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses PA21 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- PA21 Safety and Efficacy in Adult Chinese SubjectsCompletedPhase 3Vifor Fresenius Medical Care Renal PharmaNCT03644264Written as PA21How we know
- A Long-term Study of PA21 in Hemodialysis Patients With HyperphosphatemiaCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01833494Written as PA21How we know
- A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With HyperphosphatemiaCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01850641Written as PA21How we know
- A Phase III Study of PA21 in Hemodialysis Patients With HyperphosphatemiaCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01850602Written as PA21How we know
- PA21 Phase II Clinical Study in Hemodialysis Patients With HyperphosphatemiaCompletedPhase 2Kissei Pharmaceutical Co., Ltd.NCT01521494Written as PA21How we know
- A Phase III Study of PA21 in Peritoneal Dialysis Patients With HyperphosphatemiaCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01852682Written as PA21How we know
- A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis PatientsCompletedPhase 3Vifor PharmaNCT01324128Written as PA21 (2.5 g tablet containing 500 mg iron)How we know
- A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis PatientsCompletedPhase 3Vifor PharmaNCT01464190Written as PA21 (2.5 g tablet containing 500 mg iron)How we know
- A Drug-Drug Interaction Study of Losartan and PA21CompletedPhase 1Vifor PharmaNCT01324752Written as PA21 and Losartan with FoodHow we know
- A Drug-Drug Interaction Study of Warfarin and PA21CompletedPhase 1Vifor PharmaNCT01477424Written as PA21How we know
- A Drug-Drug Interaction Study of Digoxin and PA21CompletedPhase 1Vifor PharmaNCT01477411Written as PA21How we know
- A Drug-Drug Interaction Study of Omeprazole and PA21CompletedPhase 1Vifor PharmaNCT01452906Written as PA21 and Omeprazole with foodHow we know
- A Drug-Drug Interaction Study of Furosemide and PA21CompletedPhase 1Vifor PharmaNCT01438359Written as PA21 and Furosemide with foodHow we know